Under one in 10 patients who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it publishes its initial guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable access to this class of drugs.
Based on estimates, over two billion could be obese by 2030 if no action is taken.
"Our new guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major obstacles to widespread access to the treatments that can assist patients in reducing considerable weight, says the organization.
GLP-1 Therapy Shortage
Despite the present most favorable outlook, the supply of such drugs might only reach around 100 million people – under 10% of the global need, according to the WHO.
The advice urges governments and firms to expand availability, by measures including licensing agreements.
Exclusive production rights on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Jabs Work
These medications imitate a body's own hormone to slow digestion, curb appetite and enhance feelings of fullness so people consume fewer calories.
Individuals commonly see weight reduction in the initial weeks of beginning the regular doses.
Evidence suggests people may put most of the weight back on a year later of discontinuing the treatment, because their usual appetite resume.
Being above a healthy weight elevates your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity concerns individuals in all nations and was associated with millions of deaths worldwide in 2024, per the WHO.
